Mesenchymal Stem Cells Market

Mesenchymal Stem Cells Market Size:

The global mesenchymal stem cells market size reached US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.9 Billion by 2032, exhibiting a growth rate (CAGR) of 11.75% during 2024-2032. The market is mainly driven by the growing prevalence of chronic diseases, advancements in stem cell research, and increasing clinical trials. In line with this, enhanced regulatory support and investments in healthcare further propel the development and adoption of MSC-based therapies globally, hence driving the market growth.

Mesenchymal Stem Cells Market Analysis:

• Major Market Drivers: The market is primarily driven by the rising prevalence of chronic disease across the world, advancements in stem cell research and technology, and rising demand for regenerative medicine. In line with this, supportive regulatory frameworks, substantial investment from public and private sectors along with the growing number of clinical trials and approvals for MSC-based therapies significantly contribute to mesenchymal stem cells market growth. Furthermore, collaborative efforts among biotech companies, research institutions, and healthcare providers further accelerate the development and commercialization of mesenchymal stem cells expanding its therapeutic applications and market reach.
• Key Market Trends: Key trends in the market include significant advancements in biotechnology enhancing MSC therapy applications and broadening the scope of disease which can be treated by mesenchymal stem cells. In line with this, the market is also witnessing a shift towards allogeneic MSC therapies because of their off-the-shelf availability and scalability. Furthermore, regulatory approvals are accelerating mainly in North America and Europe which promotes wider adoption of MSC- based treatments. There is also a growing focus on partnerships between academic institutions and various biopharmaceutical companies which aims at driving innovations and clinical trials in MSC research.
• Geographical Trends: Geographical trends in the mesenchymal stem cells market have shown significant variations. North America is leading the market mainly due to its advanced healthcare infrastructure and abundant research funding. Europe follows closely, driven by regulatory support and an increasing focus on regenerative medicine. Asia Pacific is emerging as a fast-growing region mainly fueled by increasing investment in healthcare technologies and the rising prevalence of chronic disease. In line with this, countries like China and India are becoming key players because of improvements in regulatory frameworks and growing biotechnology sectors. These trends highlight global expansion and regional variances in the adoption of MSC therapies.
• Competitive Landscape: Some of the major market players in the mesenchymal stem cells industry include ATCC, Axol Bioscience Ltd., Cell Applications Inc., Celprogen Inc., Cyagen Biosciences Inc., Lonza Group AG, Merck KGaA, PromoCell GmbH, STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc., among many others.
• Challenges and Opportunities: The market faces various challenges including the complexity of scaling up the production and ensuring consistent quality across all the batches. Regulatory hurdles also vary significantly in various regions which in turn affect market entry. However, opportunities abound, including advancements in MSC research that could lead to breakthrough therapies for chronic diseases. There is also an increasing interest in using MSCs in personalized medicine and in expanding their applications further beyond traditional therapeutics into areas like tissue engineering and 3D bioprinting. The rising demand for regenerative treatments across the world offers a vast potential market for MSC-based therapies.
   

Mesenchymal Stem Cells Market Trends:

Increasing Collaboration and Partnerships

Strategic partnerships and collaborations between biotech companies, research institutions and various healthcare providers play an important role in accelerating the development and commercialization of mesenchymal stem cell (MSC) therapies. These partnerships generally combine diverse expertise, resources and technology enabling more efficient clinical trials and faster regulatory approvals. For instance, in 2024, Pluristyx and Resilience announced a partnership to streamline the development of iPSC-derived therapies with Pluristyx generating clinical grade iPSCs and Resilience handling downstream GMP manufacturing. The collaboration provides a straightforward pathway to accelerate the transition of promising iPSC therapies from early-stage development to clinical manufacturing. This cooperative approach does not only speed up the time-to-market for MSC-based treatments but also expands their therapeutic applications, further improving patient outcomes across various medical conditions.

Increasing Investment and Funding

Significant investments from public and private sectors in stem cell research and development are fueling innovations and expanding the mesenchymal stem cells (MSC) market. For instance, the Government of India (GoI) has provided substantial support for stem cell research through funding agencies like ICMR, DBT, and DST, resulting in advanced infrastructure at over 40 institutes. The National Guidelines for Stem Cell Research (NGSCR) 2017 and New Drugs and Clinical Trial Rules, 2019 regulate this field. ICMR allocated funds of Rs. 4.36 crore in 2019, Rs. 68.82 lakh in 2020, and Rs. 3.08 crore in 2021. These funds support advancements in MSC technology, clinical trials, and new therapeutic applications, driving market growth and enhancing the potential of MSC-based treatments.

Technological Advancements in Stem Cell Technology

Advancements in stem cell technology have significantly bolstered the therapeutic potential and application range of mesenchymal stem cells (MSCs). Continuous innovations in MSC isolation techniques ensure the purity and viability of harvested cells, while advancements in culture methods enhance their proliferation and longevity. Improved differentiation protocols allow for more precise conversion of MSCs into desired cell types, optimizing their use in regenerative medicine. For instance, an innovative new robot, the CellQualiaTM Intelligent Cell Processing System, is being trialed by the Medicines and Healthcare products Regulatory Agency (MHRA) to grow stem cells. This system has the potential to bring safer and more cost-effective treatments to people with a wide range of diseases, offering new hope to patients with serious diseases such as Parkinson’s. The trial is part of a UK-based international research program involving various organizations. These technological strides enable the development of more effective MSC-based therapies for a variety of conditions, including tissue repair, immune modulation, and disease modeling, thereby driving the growth and diversification of the MSC market.

Mesenchymal Stem Cells Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product & services, type, source of isolation, indication, and application.

Breakup by Product & Services:

• Products
  • Cells and Cell Lines
  • Kits, Media, and Reagents
  • Others
• Services
   

Products accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product & services. This includes products (cells and cell lines, kits, media, and reagents and others), and services. According to the report, products represented the largest segment.

In the rapidly evolving mesenchymal stem cells market, products hold the majority share, driven by their widespread applications in regenerative medicine and therapeutic treatments. The demand for these products is fueled by the increasing prevalence of chronic diseases, such as cardiovascular disorders and autoimmune diseases, where MSCs show potential due to their ability to promote tissue repair and modulate immune responses. Cardiovascular diseases (CVDs) are responsible for approximately 17.9 million deaths annually, making them the leading global cause of death. CVDs encompass various heart and blood vessel disorders, such as coronary heart disease and strokes. More than 80% of CVD-related deaths are due to heart attacks and strokes, with a third occurring prematurely in individuals under 70 years old. Furthermore, advancements in biotechnology that enhance the efficacy and safety of MSC-based products continue to propel mesenchymal stem cells market growth, attracting significant investments from healthcare companies and research institutions.

Breakup by Type:

• Autologous
• Allogeneic
   

Allogeneic holds the largest share of the industry

A detailed breakup and analysis of the market based on the type have also been provided in the report. This includes autologous and allogeneic. According to the report, allogeneic accounted for the largest market share.

Allogeneic mesenchymal stem cells (MSCs) dominate the MSC market, holding the largest share due to their significant advantages over autologous MSCs, including ready availability and immediate usability. These cells are sourced from donors and can be used across multiple patients without the need for individual donor matching, greatly simplifying the treatment process. This broad applicability is particularly valuable in acute medical settings and for diseases requiring immediate intervention. The scalability of allogeneic MSCs enables mass production, reducing costs and facilitating widespread clinical use. Ongoing research and clinical trials continue to validate their safety and efficacy, further encouraging their adoption in therapeutic applications.

Breakup by Source of Isolation:

• Bone Marrow
• Cord Blood
• Peripheral Blood
• Fallopian Tube
• Fetal Liver
• Lung
• Adipose Tissues
   

Bone Marrow represents the leading market segment 

The report has provided a detailed breakup and analysis of the market based on the source of isolation. This includes bone marrow, cord blood, peripheral blood, fallopian tube, fetal liver, lung and adipose tissues. According to the report, bone marrow represented the largest segment.

Bone marrow-derived mesenchymal stem cells (MSCs) represent the leading segment in the MSC market, primarily due to their well-documented history and proven efficacy in various therapeutic applications. These cells are the most extensively studied type of MSCs, known for their potent regenerative capabilities and ability to differentiate into various cell types including bone, cartilage, and muscle. The widespread use of bone marrow MSCs in clinical settings, ranging from orthopedics to cardiology, underscores their versatility and reliability. Furthermore, the established extraction and cultivation techniques make bone marrow MSCs a preferred choice for researchers and healthcare providers, driving their prominence in the market.

Breakup by Indication:

• Bone and Cartilage Repair
• Cardiovascular Disease
• Inflammatory and Immunological Diseases
• Liver Diseases
• Cancer
• GvHD
• Others
   

Cardiovascular Disease exhibits a clear dominance in the market 

A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes bone and cartilage repair, cardiovascular disease, inflammatory and immunological diseases, liver diseases, cancer, GvHD and others. According to the report, cardiovascular disease accounted for the largest market share.

The application of MSCs in treating cardiovascular diseases exhibits clear dominance within the mesenchymal stem cells market. This is attributed to the critical need for innovative treatments in managing heart conditions, which remain a leading cause of death globally. MSCs are particularly valued for their ability to regenerate damaged heart tissue and modulate immune responses, offering potential breakthroughs in heart repair and recovery. Their anti-inflammatory properties and capability to promote angiogenesis are critical in treating myocardial infarction and heart failure. Ongoing clinical trials and research are continuously uncovering new potentials of MSCs in cardiovascular therapies, reinforcing their dominant position in the market.

Breakup by Application:

• Disease Modelling
• Drug Development and Discovery
• Stem Cell Banking
• Tissue Engineering
• Toxicology Studies
   

Disease Modelling dominates the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes disease modelling, drug development and discovery, stem cell banking, tissue engineering, toxicology studies. According to the report, disease modelling represented the largest segment.

Disease modelling has emerged as a dominant segment within the mesenchymal stem cells (MSCs) market, primarily driven by the growing need for advanced models in drug discovery and development. MSCs are increasingly used to simulate a wide range of diseases in vitro, including cancer, neurodegenerative disorders, and autoimmune diseases. This application facilitates the understanding of disease mechanisms and the evaluation of potential therapeutic interventions in a controlled environment. The versatility and adaptability of MSCs make them ideal for these purposes, enabling researchers to observe disease progression and drug responses more accurately. Consequently, the demand for MSCs in disease modelling continues to grow, significantly influencing the market's dynamics.

Breakup by Region:

• North America
  • United States
  • Canada
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America leads the market, accounting for the largest mesenchymal stem cells market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for mesenchymal stem cells.

North America leads the mesenchymal stem cells (MSCs) market, accounting for the largest market share due to its robust healthcare infrastructure, significant investments in stem cell research, and supportive regulatory environment. The region boasts numerous leading biotechnology companies and research institutions driving innovation and development in MSC applications. Additionally, the high prevalence of chronic diseases, such as cardiovascular and autoimmune disorders, fuels the demand for advanced therapeutic solutions, including MSC-based treatments. For instance, Heart disease is the leading cause of death in the United States, claiming about 695,000 lives in 2021 and costing the US about $239.9 billion annually. Coronary heart disease is the most common type, affecting about 1 in 20 adults. Early action is crucial for heart attacks, which occur every 40 seconds in the US. Furthermore, government initiatives and funding support stem cell research and clinical trials, solidifying North America's position at the forefront of the MSC market and fostering continual growth and advancements in this field.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the mesenchymal stem cells industry include ATCC, Axol Bioscience Ltd., Cell Applications Inc., Celprogen Inc., Cyagen Biosciences Inc., Lonza Group AG, Merck KGaA, PromoCell GmbH, STEMCELL Technologies Inc. and Thermo Fisher Scientific Inc., etc.
  
  (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
   
• Key players in the mesenchymal stem cells (MSC) market are diversifying their offerings to meet the evolving needs of regenerative medicine across various therapeutic areas, including orthopedics, neurology, and cardiology. Companies are increasingly integrating advanced technologies into their MSC research and development, such as gene editing and 3D bioprinting, to enhance therapeutic outcomes. For example, Thermo Fisher Scientific launched the Gibco CTS DynaCellect Magnetic Separation System, a closed and automated instrument that provides scalable, flexible, and optimized cell therapy manufacturing by ensuring high cell purity, isolation efficiency, and recovery of target cells. These innovations, along with enhanced regulatory support and growing clinical trials, are crucial in driving the adoption of mesenchymal stem cells therapies, thereby boosting the mesenchymal stem cells market growth.

Mesenchymal Stem Cells Market Recent Developments:

• In 2023, ATCC and USP announced a strategic collaboration to provide solutions and standards that help customers deliver safe and high-quality biologics to patients more rapidly. The two organizations will jointly provide co-branded reference materials and reference standards to advance the quality and development of biologic medicines and therapies.
• In 2024, Axol Bioscience launched a new axoCells Atrial Cardiomyocyte kit to enable better modeling of arrhythmia and cardiotoxicity. The all-in-one kit provides a solution for researchers studying atrial fibrillation and other heart conditions.
• In 2024, Lonza Group AG signed an agreement to acquire the Genentech manufacturing facility in Vacaville (US) from Roche for USD 1.2 billion, aiming to enhance its large-scale biologics manufacturing capacity. This acquisition is expected to close in the second half of 2024, integrating the Vacaville site into Lonza's Biologics division, expanding its presence in the US, and updating its sales growth guidance to 12 – 15% CAGR.

Mesenchymal Stem Cells Market Report Scope:

Key Questions Answered in This Report:

• How has the global mesenchymal stem cells market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global mesenchymal stem cells market?
• What is the impact of each driver, restraint, and opportunity on the global mesenchymal stem cells market?
• What are the key regional markets?
• Which countries represent the most attractive mesenchymal stem cells market?
• What is the breakup of the market based on the products and services?
• Which is the most attractive products and services in the mesenchymal stem cells market?
• What is the breakup of the market based on the type?
• Which is the most attractive type in the mesenchymal stem cells market?
• What is the breakup of the market based on the source of isolation?
• Which is the most attractive source of isolation in the mesenchymal stem cells market?
• What is the breakup of the market based on the indication?
• Which is the most attractive indication in the mesenchymal stem cells market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the mesenchymal stem cells market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global mesenchymal stem cells market?

Key Benefits for Stakeholders

• IMARC’s report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the mesenchymal stem cells market from 2018-2032.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global mesenchymal stem cells market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the mesenchymal stem cells industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.